Stay updated on Eli Lilly and Company Press Releases
Sign up to get notified when there's something new on the Eli Lilly and Company Press Releases page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FqB4o2xlL8pahxXRb-YpQ8KSPq6o.uncropped.jpg&w=3840&q=75)
Latest updates to the Eli Lilly and Company Press Releases page
- ChecktodayNo Change Detected
- Check2 days agoChange DetectedEli Lilly has announced the date for its second-quarter 2024 financial results and a conference call on August 8, 2024, while the previous announcement regarding Melissa Seymour joining as executive vice president of Global Quality has been removed.SummaryDifference14%
- Check3 days agoNo Change Detected
- Check4 days agoNo Change Detected
- Check5 days agoNo Change Detected
- Check18 days agoChange DetectedLilly has announced the acquisition of Morphic to enhance outcomes for patients with Inflammatory Bowel Disease by expanding their immunology pipeline with oral integrin therapies.SummaryDifference15%
- Check24 days agoChange DetectedThe webpage value has changed to 'Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease on July 2, 2024'. This represents a significant update regarding the approval of a new treatment for Alzheimer's disease by Eli Lilly and Company.SummaryDifference15%
- Check31 days agoChange DetectedThe webpage content has been updated to reflect that Lilly has shifted its focus from participating in the Goldman Sachs 45th Annual Global Healthcare Conference to collaborating with OpenAI to discover novel medicines for treating drug-resistant bacteria.SummaryDifference14%
- Check32 days agoChange DetectedThe value on the webpage has changed from 'Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site' to 'Lilly Declares Third-Quarter 2024 Dividend of $1.30 per share.' This represents a shift from investment in manufacturing to dividend declaration.SummaryDifference15%
- Check35 days agoChange DetectedThe value of Lilly's tirzepatide reducing obstructive sleep apnea (OSA) severity has been updated, with up to 51.5% of participants now meeting the criteria for disease resolution.SummaryDifference15%
Stay in the know with updates to Eli Lilly and Company Press Releases
Enter your email address, and we'll notify you when there's something new on the Eli Lilly and Company Press Releases page.